<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Phenobarbital" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Phenobarbital</book-part-id>
      <title-group>
        <title>Phenobarbital</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>7</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Phenelzine" document-type="chapter">Phenelzine</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Phentermine" document-type="chapter">Phentermine</related-object>
    </book-part-meta>
    <body>
      <sec id="Phenobarbital.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Phenobarbital.Introduction">
          <title>Introduction</title>
          <p content-type="pubmed-excerpt">Phenobarbital is a barbiturate that is widely used as a sedative and an antiseizure medication. Phenobarbital has been linked to rare instances of idiosyncratic liver injury that can be severe and even fatal.</p>
        </sec>
        <sec id="Phenobarbital.Background">
          <title>Background</title>
          <p>Phenobarbital (fee" noe bar' bi tal) is a barbiturate and is believed to act as a nonselective depressant. Phenobarbital also has anticonvulsant activity and is thought to act by suppressing spread of seizure activity by enhancing the effect of gamma aminobutyric acid (GABA), raising the seizure threshold. Phenobarbital was introduced into clinical medicine in 1911 but was never subjected to critical controlled studies to demonstrate safety and efficacy. For these reasons, phenobarbital is now considered of unproven benefit in controlling seizures. Nevertheless, it is commonly used for prevention and management of partial and generalized seizures, usually as an adjunctive agent in combination with other anticonvulsants. Phenobarbital is also used for sedation and insomnia although its use for these conditions is now uncommon. Phenobarbital is also used in fixed combinations with other antispasmodics or anticholinergic agents and used for gastrointestinal complaints, including irritable bowel syndrome. The typical starting dose in treating seizures in adults is 60 to 100 mg in three divided doses daily. Oral formulations of tablets or capsules of 15, 16, 30, 60, 90 and 100 mg are available in multiple generic forms. Parenteral formations and oral elixirs for pediatric use are also available. Phenobarbital has declined in general use in recent years with availability of more efficacious and better tolerated agents. Its major advantage is low cost, but it is more sedating than other anticonvulsants. Frequent side effects include drowsiness, sedation, hypotension, and skin rash. Uncommon but potentially severe adverse events included severe sedation, dependence, hypersensitivity reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
        </sec>
        <sec id="Phenobarbital.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Prospective studies suggest that less than 1% of subjects develop elevations in serum aminotransferase levels during long term phenobarbital therapy. Clinically apparent hepatotoxicity from phenobarbital is rare but can be abrupt in onset, severe and even fatal. Phenobarbital hepatotoxicity typically occurs in the setting of anticonvulsant hypersensitivity syndrome with onset of fever, rash, facial edema, lymphadenopathy, elevations in white count and eosinophilia occurring 1 week to several months after starting therapy. Liver involvement is common, but is usually mild and anicteric and overshadowed by other features of hypersensitivity (rash, fever). In some cases, hepatic involvement is more prominent with marked elevations in serum enzyme levels, jaundice and even signs of hepatic failure. The typical pattern of serum enzyme elevations is mixed, but can be hepatocellular or cholestatic. Liver biopsy shows mixed hepatitis-cholestatic injury with prominence of eosinophils and occasionally granulomata. Re-exposure usually results in recurrence and should be avoided.</p>
          <p>Likelihood score: B (likely rare cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Phenobarbital.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism of phenobarbital hepatotoxicity is thought to be hypersensitivity or an immunological response to a metabolically generated drug-protein complex.</p>
        </sec>
        <sec id="Phenobarbital.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>Phenobarbital hepatotoxicity is usually rapidly reversible with improvements beginning within 5 to 7 days of stopping the drug and being complete within 1 to 2 months. In cases of severe injury, progression to acute liver failure and death can occur. Corticosteroids have been used but with uncertain effectiveness. Prolonged cholestasis can occur, but chronic injury and vanishing bile duct syndrome have not been reported from phenobarbital therapy. Cross reactivity with other aromatic anticonvulsants (phenytoin, carbamazepine, primidone, and lamotrigine) is common but not invariable. Patients with hypersensitivity to phenobarbital should be monitored carefully if they are to start other aromatic anticonvulsants.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="Anticonvulsants" document-type="chapter">Anticonvulsants</related-object>, <related-object link-type="booklink" source-id="livertox" document-id="Sedatives_Hypnotics" document-type="chapter">Sedatives and Hypnotics</related-object></p>
        </sec>
      </sec>
      <sec id="Phenobarbital.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Phenobarbital &#x02013; Generic, Luminal&#x000ae; Sodium</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Anticonvulsants</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Phenobarbital">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Phenobarbital.CHEMICAL_FORMULA_AND_STRUC">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Phenobarbital.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Phenobarbital.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Phenobarbital.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Phenobarbital.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Phenobarbital.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Phenobarbital.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Phenobarbital</td>
                <td headers="hd_h_Phenobarbital.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://134970852">50-06-6</ext-link>
                </td>
                <td headers="hd_h_Phenobarbital.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C12-H12-N2-O3</td>
                <td headers="hd_h_Phenobarbital.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="134970852" document-id-type="sid" document-type="summary" object-id="134970852" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Phenobarbital.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 30 July 2020</p>
        <p>Abbreviations used: DRESS, drug rash with eosinophilia and systemic symptoms; SJS/TEN, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p>
        <ref-list id="Phenobarbital.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Phenobarbital.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Anticonvulsants. In, Zimmerman, HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999: pp. 498-516.<annotation><p><italic toggle="yes">(Expert review of anticonvulsants and liver injury published in 1999; mentions that liver injury from phenobarbital is rare, but it has been implicated in at least 15 cases of clinically apparent injury, both hepatocellular and cholestatic).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Phenobarbital.REF.pirmohamed.2013">
            <mixed-citation publication-type="book">Pirmohamed M, Leeder SJ. Anticonvulsant agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013: pp 423-41.<annotation><p><italic toggle="yes">(Review of anticonvulsant induced liver injury mentions that clinically apparent hepatotoxicity from phenobarbital is rare and that cross sensitivity to hepatic injury from other aromatic anticonvulsants occurs, but is not invariable).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Phenobarbital.REF.smith.2018">
            <mixed-citation publication-type="book">Smith MD, Metcalf CS, Wilcox KS. Pharmacology of the epilepsies. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 303-26.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Phenobarbital.REF.birch.1936.478">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Birch</surname>
                  <given-names>CA</given-names>
                </name>
              </person-group>
              <article-title>Jaundice due to phenobarbital.</article-title>
              <source>Lancet</source>
              <year>1936</year>
              <volume>i</volume>
              <fpage>478</fpage>
              <lpage>9</lpage>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.welton.1950.232">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Welton</surname>
                  <given-names>DG</given-names>
                </name>
              </person-group>
              <article-title>Exfoliative dermatitis and hepatitis due to phenobarbital.</article-title>
              <source>J Am Med Assoc</source>
              <year>1950</year>
              <volume>143</volume>
              <fpage>232</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(25 year old pregnant woman developed rash, followed by facial and peripheral edema, itching, erythema, desquamation, and high fever 6 weeks after starting phenobarbital [white blood count 73,000, 32% eosinophils] and was jaundiced for a few weeks but ultimately recovered).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15415251</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.mcgeachy.1953.600">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>McGeachy</surname>
                  <given-names>TE</given-names>
                </name>
                <name name-style="western">
                  <surname>Bloomer</surname>
                  <given-names>WE</given-names>
                </name>
              </person-group>
              <article-title>The phenobarbital sensitivity syndrome.</article-title>
              <source>Am J Med</source>
              <year>1953</year>
              <volume>14</volume>
              <fpage>600</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(3 cases of severe phenobarbital reactions seen between 1933 and 1947; two men and one woman, ages 27 to 41 years, developing rash, desquamation, fever, delirium and jaundice within 1-2 weeks of starting drug; one instance was fatal).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">13040367</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.pagliaro.1969.938">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pagliaro</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Campesi</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Aguglia</surname>
                  <given-names>F.</given-names>
                </name>
              </person-group>
              <article-title>Barbiturate jaundice. Report of a case due to a barbital-containing drug, with positive rechallenge to phenobarbital.</article-title>
              <source>Gastroenterology</source>
              <year>1969</year>
              <volume>56</volume>
              <fpage>938</fpage>
              <lpage>43</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(31 year old woman developed rash, fever and facial edema after 2 doses of "barbital" and by 7 days developed jaundice [bilirubin 24.1 mg/dL, ALT 200 U/L, Alk P 15 BU] which was prolonged; rechallenge with phenobarbital caused recurrence of fever, rash and jaundice [19 mg/dL]; three biopsies were done, but vanishing bile duct syndrome was evidently not present).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">4238546</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.weisburst.1976.126">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Weisburst</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Self</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Peace</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Cooper</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Jaundice and rash associated with the use of phenobarbital and hydrochlorothiazide.</article-title>
              <source>South Med J</source>
              <year>1976</year>
              <volume>69</volume>
              <fpage>126</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(18 year old woman developed rash followed by fever, anorexia, lymphadenopathy and jaundice [bilirubin 7.2 mg/dL, AST 250 U/L, Alk P 350 U/L], with rapid resolution although no mention of drug being stopped).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">128822</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.evans.1976.439">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Evans</surname>
                  <given-names>WE</given-names>
                </name>
                <name name-style="western">
                  <surname>Self</surname>
                  <given-names>TH</given-names>
                </name>
                <name name-style="western">
                  <surname>Weisburst</surname>
                  <given-names>MR</given-names>
                </name>
              </person-group>
              <article-title>Phenobarbital-induced hepatic dysfunction.</article-title>
              <source>Drug Intell Clin Pharm</source>
              <year>1976</year>
              <volume>10</volume>
              <fpage>439</fpage>
              <lpage>43</lpage>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.thirunavukkaram.1979.1261">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Thirunavukkaram</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Merk</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Fitzgerald</surname>
                  <given-names>JF</given-names>
                </name>
              </person-group>
              <article-title>Near-fatal phenobarbital hepatotoxicity in an 8 year old male.</article-title>
              <source>Gastroenterology</source>
              <year>1979</year>
              <volume>76</volume>
              <fpage>1261</fpage>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.shapiro.1980.270">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Shapiro</surname>
                  <given-names>PA</given-names>
                </name>
                <name name-style="western">
                  <surname>Antonioli</surname>
                  <given-names>DA</given-names>
                </name>
                <name name-style="western">
                  <surname>Peppercorn</surname>
                  <given-names>MA</given-names>
                </name>
              </person-group>
              <article-title>Barbiturate-induced submassive hepatic necrosis.</article-title>
              <source>Am J Gastroenterol</source>
              <year>1980</year>
              <volume>74</volume>
              <fpage>270</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(71 year old woman developed rash on phenytoin and was switched to mephobarbital and 3 months later developed anorexia and fatigue followed by jaundice 6 weeks later [bilirubin 5.3 mg/dL, ALT 837 U/L, Alk P 320 U/L], improved slowly but relapsed with restarting phenobarbital; biopsy showed submassive necrosis, ultimately recovering completely; no features of hypersensitivity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7468565</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.jacobi.1980.712">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Jacobi</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Thorbeck</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Ritz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Janssen</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Schmidts</surname>
                  <given-names>HL</given-names>
                </name>
              </person-group>
              <article-title>Fatal hepatotoxicity in child on phenobarbitone and sodium valproate.</article-title>
              <source>Lancet</source>
              <year>1980</year>
              <volume>1</volume>
              <fpage>712</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Child given valproate [36 mg/kg] and phenobarbital for 3 months developed confusion and coma [bilirubin 9.7 mg/dL, ALT 60 U/L, high ammonia and protime], ultimately dying; more likely due to valproate than phenobarbital hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6103126</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.spielberg.1981.722">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Spielberg</surname>
                  <given-names>SP</given-names>
                </name>
                <name name-style="western">
                  <surname>Gordeon</surname>
                  <given-names>GB</given-names>
                </name>
                <name name-style="western">
                  <surname>Blake</surname>
                  <given-names>DA</given-names>
                </name>
                <name name-style="western">
                  <surname>Goldstein</surname>
                  <given-names>DA</given-names>
                </name>
                <name name-style="western">
                  <surname>Herlong</surname>
                  <given-names>HF</given-names>
                </name>
              </person-group>
              <article-title>Predisposition to phenytoin hepatotoxicity assessed in vitro.</article-title>
              <source>N Engl J Med</source>
              <year>1981</year>
              <volume>305</volume>
              <fpage>722</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(3 patients with phenytoin hepatotoxicity had dose dependent cytotoxicity of lymphocytes exposed to microsomal metabolized drug [arene oxides]; clinical onset arose 4, 4 and 1 week after starting phenytoin, with rash, fever and jaundice; [bilirubin 7.8, 11.5 and 0.5 g/dL, AST 790, 2340 and 62 U/L, eosinophils 9%, 10% and 10%], all 3 recovered).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6790991</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.lane.1984.94">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lane</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Peterson</surname>
                  <given-names>EA</given-names>
                </name>
              </person-group>
              <article-title>Hepatitis as a manifestation of phenobarbital hypersensitivity.</article-title>
              <source>South Med J</source>
              <year>1984</year>
              <volume>77</volume>
              <fpage>94</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(4 year old boy developed fever and rash about 1 week after starting phenobarbital and 1 week later was found to have ALT 273 U/L [no bilirubin reported], rapidly improving with stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6695234</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.knutsen.1984.558">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Knutsen</surname>
                  <given-names>AP</given-names>
                </name>
                <name name-style="western">
                  <surname>Anderson</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Satayaviboon</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Slavin</surname>
                  <given-names>RG</given-names>
                </name>
              </person-group>
              <article-title>Immunologic aspects of phenobarbital hypersensitivity.</article-title>
              <source>J Pediatr</source>
              <year>1984</year>
              <volume>105</volume>
              <fpage>558</fpage>
              <lpage>63</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Seven patients with hypersensitivity reactions arising 2-23 days after starting phenobarbital with fever and a pruritic rash which was confluent and desquamating; 2 patients had abnormal liver tests, but without jaundice; 3 had eosinophilia, 3 IgE elevations; 2 decreased C4 levels; several had positive lymphocyte stimulation tests to phenytoin or phenobarbital).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6332892</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.fonseca.1984.187">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Fonseca</surname>
                  <given-names>JC</given-names>
                </name>
                <name name-style="western">
                  <surname>Azulay</surname>
                  <given-names>DR</given-names>
                </name>
                <name name-style="western">
                  <surname>Rozembau</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Azulay</surname>
                  <given-names>RD</given-names>
                </name>
              </person-group>
              <comment>[Hypersensitivity syndrome caused by phenytoins and phenobarbital]</comment>
              <source>Med Cutan Ibero Lat Am</source>
              <year>1984</year>
              <volume>12</volume>
              <fpage>187</fpage>
              <lpage>92</lpage>
              <comment>Portuguese.</comment>
              <pub-id pub-id-type="pmid">6237236</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.kahn.1984.1677">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kahn</surname>
                  <given-names>HD</given-names>
                </name>
                <name name-style="western">
                  <surname>Faguet</surname>
                  <given-names>GB</given-names>
                </name>
                <name name-style="western">
                  <surname>Agee</surname>
                  <given-names>JF</given-names>
                </name>
                <name name-style="western">
                  <surname>Middleton</surname>
                  <given-names>HM</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced liver injury. In vitro demonstration of hypersensitivity to both phenytoin and phenobarbital.</article-title>
              <source>Arch Intern Med</source>
              <year>1984</year>
              <volume>144</volume>
              <fpage>1677</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(16 year old girl developed fever, facial edema, lymphadenopathy and rash 3 weeks after starting phenobarbital and phenytoin; stopping phenytoin had no effect, but she improved with stopping phenobarbital and had positive lymphocyte stimulation tests to both).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">6466024</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.palomeque.1986.328">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Palomeque</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Dom&#x000e9;nech</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Mart&#x000ed;nez-Guti&#x000e9;rrez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Lequerica</surname>
                  <given-names>P.</given-names>
                </name>
              </person-group>
              <comment>[Severe hypersensitivity to phenobarbital with erythema multiforme, cholestatic hepatitis and aplastic anemia]</comment>
              <source>An Esp Pediatr</source>
              <year>1986</year>
              <volume>24</volume>
              <fpage>328</fpage>
              <lpage>30</lpage>
              <comment>Spanish.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(11 year old girl developed rash, fever, adenopathy, somnolence and facial edema 4 weeks after starting phenobarbital [bilirubin 6.7 to 42.8 mg/dL, ALK 1380 to 2980 U/L, Alk P 855 to 3146 U/L], with confluent necrosis and central collapse on liver biopsy, transient episode of aplastic anemia during recovery).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3740671</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.shear.1988.1826">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Shear</surname>
                  <given-names>NH</given-names>
                </name>
                <name name-style="western">
                  <surname>Spielberg</surname>
                  <given-names>SP</given-names>
                </name>
              </person-group>
              <article-title>Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk.</article-title>
              <source>J Clin Invest</source>
              <year>1988</year>
              <volume>82</volume>
              <fpage>1826</fpage>
              <lpage>32</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Lymphocyte cytotoxicity found in response to drug metabolites from 53 patients with hypersensitivity to anticonvulsants, including 35/36 to phenytoin, 22/27 to phenobarbital and 25/27 to carbamazepine; 51% had hepatitis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3198757</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.roberts.1990.235">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Roberts</surname>
                  <given-names>EA</given-names>
                </name>
                <name name-style="western">
                  <surname>Spielberg</surname>
                  <given-names>SP</given-names>
                </name>
                <name name-style="western">
                  <surname>Goldbach</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Phillips</surname>
                  <given-names>MJ</given-names>
                </name>
              </person-group>
              <article-title>Phenobarbital hepatotoxicity in an 8-month-old infant.</article-title>
              <source>J Hepatol</source>
              <year>1990</year>
              <volume>10</volume>
              <fpage>235</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(8 month old boy with seizures given phenobarbital for 2 weeks developed rash followed by fever with eosinophilia, atypical lymphocytosis and jaundice [bilirubin 2.9 mg/dL, ALT 430 U/L, Alk P 135 U/L], slow recovery, positive lymphocyte cytotoxicity test).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2332596</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.horsmans.1991.648">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Horsmans</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Larrey</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Pessayre</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Rueff</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Degott</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Benhamou</surname>
                  <given-names>JP</given-names>
                </name>
              </person-group>
              <comment>[Atrium-related hepatitis. Report of four cases]</comment>
              <source>Gastroenterol Clin Biol</source>
              <year>1991</year>
              <volume>15</volume>
              <fpage>648</fpage>
              <lpage>52</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Atrium, a fixed combination of phenobarbital and two carbamates, was implicated in 4 cases of hepatotoxicity arising 1-4 months after starting [normal bilirubin, ALT 1.5-21 fold elevated] with mild symptoms of asthenia, but no fever or rash and resolving within 1-3 months of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">1684328</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.pariente.1992.485">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Pariente</surname>
                  <given-names>EA</given-names>
                </name>
                <name name-style="western">
                  <surname>Mineur</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <comment>[Atrium-induced hepatitis with autoimmune pattern]</comment>
              <source>Gastroenterol Clin Biol</source>
              <year>1992</year>
              <volume>16</volume>
              <fpage>485</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Patient developed fatigue one month after starting Atrium and clomethacine [bilirubin normal, ALT 16.5 times ULN, GGT 10 times ULN, ANA 1:160], resolved with stopping but recurrence of fatigue, ALT elevation and ANA/SMA positivity with two rechallenges: HLA A1, A9, B8, B27).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">1526409</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.handfieldjones.1993.175">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Handfield-Jones</surname>
                  <given-names>SE</given-names>
                </name>
                <name name-style="western">
                  <surname>Jenkins</surname>
                  <given-names>RE</given-names>
                </name>
                <name name-style="western">
                  <surname>Whittaker</surname>
                  <given-names>SJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Besse</surname>
                  <given-names>CP</given-names>
                </name>
                <name name-style="western">
                  <surname>McGibbon</surname>
                  <given-names>DH</given-names>
                </name>
              </person-group>
              <article-title>The anticonvulsant hypersensitivity syndrome.</article-title>
              <source>Br J Dermatol</source>
              <year>1993</year>
              <volume>129</volume>
              <fpage>175</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(3 cases of fever and rash arising 3, 4 and 10 weeks after starting phenytoin or carbamazepine; two required steroids; only 1 had hepatitis; one died of multiorgan failure, others switched to valproate or clobazam without recurrence).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7654579</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.brocheriou.1993.305">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Brocheriou</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Zafrani</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Mavier</surname>
                  <given-names>P</given-names>
                </name>
              </person-group>
              <comment>[Severe acute hepatitis caused by Atrium]</comment>
              <source>Gastroenterol Clin Biol</source>
              <year>1993</year>
              <volume>17</volume>
              <fpage>305</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(29 year old man developed jaundice after 7 months of Atrium therapy [also on valproate and phenobarbital] with abdominal pain and jaundice [bilirubin 10 mg/dL, ALT 200-4056 U/L, ANA 1:200], biopsy showed no fat, recurrence with rechallenge of Atrium, but not valproate).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8339895</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.horsmans.1994.1075">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Horsmans</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Lannes</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Pessayre</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Larrey</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <article-title>Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate.</article-title>
              <source>J Hepatol</source>
              <year>1994</year>
              <volume>21</volume>
              <fpage>1075</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Hydroxylation index of mephenytoin [CYP 2C] was assessed in 24 patients with drug induced hepatitis, found index higher [12.4] in 3 patients with Atrium hepatitis than in controls [1.8] and other patients [2.5], attributed abnormality to a defect in mephenytoin oxidation).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7699230</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.di_martino.1994.904">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Di Martino</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Mallat</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Duvoux</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Zafrani</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Dhumeaux</surname>
                  <given-names>D</given-names>
                </name>
              </person-group>
              <comment>[Severe hepatitis caused by phenobarbital]</comment>
              <source>Gastroenterol Clin Biol</source>
              <year>1994</year>
              <volume>18</volume>
              <fpage>904</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Patient on phenobarbital for 1 month developed fever and rash followed by adenopathy and jaundice [bilirubin 8.7 mg/dL, ALT 22 times ULN, elevated protime], treated with prednisone and recovered within 1 month).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7875406</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.schneider.1995.1064">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Schneider</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Charles</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Chichmanian</surname>
                  <given-names>RM</given-names>
                </name>
                <name name-style="western">
                  <surname>Montoya</surname>
                  <given-names>ML</given-names>
                </name>
                <name name-style="western">
                  <surname>Rampal</surname>
                  <given-names>P</given-names>
                </name>
              </person-group>
              <comment>[Acute hepatitis associated with microvesicular steatosis induced by Atrium]</comment>
              <source>Gastroenterol Clin Biol</source>
              <year>1995</year>
              <volume>19</volume>
              <fpage>1064</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(37 year woman developed abdominal pain 6 months after starting Atrium [bilirubin 2.0 mg/dL, ALT 9 times ULN, Alk P 0.8 times ULN, ANA 1:1000], biopsy showed microvesicular fat; also taking carbimazole and phenytoin).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8729422</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.cayla.1995.1665">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Cayla</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Fandi</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Arnould</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Degott</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Gouffier</surname>
                  <given-names>E</given-names>
                </name>
              </person-group>
              <comment>[Atrium 300 hepatitis. A new case]</comment>
              <source>Presse Med</source>
              <year>1995</year>
              <volume>24</volume>
              <fpage>1665</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(65 year old woman was found to have ALT elevations [5 times ULN] 3 months after starting Atrium, with rapid resolution on stopping and recurrence with rechallenge; no jaundice but some fatigue).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8545391</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.wallace.1996.378">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Wallace</surname>
                  <given-names>SJ</given-names>
                </name>
              </person-group>
              <article-title>A comparative review of the adverse effects of anticonvulsants in children with epilepsy.</article-title>
              <source>Drug Saf</source>
              <year>1996</year>
              <volume>15</volume>
              <fpage>378</fpage>
              <lpage>93</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review; ALT elevations occur in 4% of children on phenytoin, 6% on valproate, 1% on carbamazepine but not with phenobarbital; mentions that severe skin reactions and Stevens-Johnson syndrome have been linked to phenobarbital use).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8968693</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.schlienger.1998.s3">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Schlienger</surname>
                  <given-names>RG</given-names>
                </name>
                <name name-style="western">
                  <surname>Shear</surname>
                  <given-names>NH</given-names>
                </name>
              </person-group>
              <article-title>Antiepileptic drug hypersensitivity syndrome.</article-title>
              <source>Epilepsia</source>
              <year>1998</year>
              <volume>39</volume>
              <supplement>Suppl 7</supplement>
              <fpage>S3</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of anticonvulsant hypersensitivity syndrome; onset 2-8 weeks after starting therapy with aromatic anticonvulsants presenting with high fever, rash, adenopathy and pharyngitis followed by organ involvement, most commonly the liver [~50%], but also hematologic, renal or pulmonary; eosinophilia, blood dyscrasias, nephritis; sometimes facial edema, oral ulcers, hepatosplenomegaly, myopathy, disseminated intravascular coagulation, atypical lymphocytosis; rash usually exanthema with pruritus, occasional follicular pustules or exfoliative dermatitis and erythroderma, erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">9798755</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.knowles.1999.489">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Knowles</surname>
                  <given-names>SR</given-names>
                </name>
                <name name-style="western">
                  <surname>Shapiro</surname>
                  <given-names>LE</given-names>
                </name>
                <name name-style="western">
                  <surname>Shear</surname>
                  <given-names>NH</given-names>
                </name>
              </person-group>
              <article-title>Anticonvulsant hypersensitivity syndrome: incidence, prevention and management.</article-title>
              <source>Drug Saf</source>
              <year>1999</year>
              <volume>21</volume>
              <fpage>489</fpage>
              <lpage>501</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of anticonvulsant hypersensitivity syndrome: triad of fever, rash and internal organ injury occurring 1-8 weeks after exposure to anticonvulsant; liver being most common internal organ involved. Occurs in 1:1000-1:10,000 initial exposures to phenytoin, carbamazepine, phenobarbital or lamotrigine, unrelated to dose, perhaps predisposed by valproate; liver injury arises 1-4 weeks after onset of rash and ranges in severity from asymptomatic ALT elevations to icteric hepatitis to acute liver failure. High mortality rate with jaundice; other organs include muscle, kidney, brain, heart and lung. Pseudolymphoma syndrome and serum sickness-like syndrome are separate complications of anticonvulsants. Role of corticosteroids uncertain; cross reactivity among the agents should be assumed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">10612272</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.lachgar.2001.173">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Lachgar</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Touil</surname>
                  <given-names>Y.</given-names>
                </name>
              </person-group>
              <comment>[The drug hypersensitivity syndrome or DRESS syndrome to phenobarbital]</comment>
              <source>Allerg Immunol (Paris)</source>
              <year>2001</year>
              <volume>33</volume>
              <fpage>173</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(78 year old woman developed rash and fever 3 weeks after starting phenobarbital [ALT 3 times ULN, eosinophilia], resolving within a month of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">11434197</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.turner.2004.s86">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Turner</surname>
                  <given-names>RB</given-names>
                </name>
                <name name-style="western">
                  <surname>Kim</surname>
                  <given-names>CC</given-names>
                </name>
                <name name-style="western">
                  <surname>Streams</surname>
                  <given-names>BN</given-names>
                </name>
                <name name-style="western">
                  <surname>Culpepper</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Haynes</surname>
                  <given-names>HA</given-names>
                </name>
              </person-group>
              <article-title>Anticonvulsant hypersensitivity syndrome associated with Bellamine S, a therapy for menopausal symptoms.</article-title>
              <source>J Am Acad Dermatol</source>
              <year>2004</year>
              <volume>50</volume>
              <issue>5</issue>
              <supplement>Suppl</supplement>
              <fpage>S86</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Patient developed fever, rash and facial edema followed by jaundice 2 months after starting Bellamine S which contains phenobarbital, belladonna and ergotamine [bilirubin 2.4 mg/dL, ALT 97 U/L, Alk P 160 U/L, 14% eosinophils], and then developed complications of herpes zoster and meningitis during prednisone therapy for the hypersensitivity, and later had recurrence during carbamazepine therapy for neuralgia).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15097937</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.autretleca.2007.1439">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Autret-Leca</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Norbert</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Bensouda-Grimaldi</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Jonville-B&#x000e9;ra</surname>
                  <given-names>AP</given-names>
                </name>
                <name name-style="western">
                  <surname>Saliba</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Bentata</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Barthez-Carpentier</surname>
                  <given-names>MA</given-names>
                </name>
              </person-group>
              <comment>[DRESS syndrome, a drug reaction which remains bad known from paediatricians]</comment>
              <source>Arch Pediatr</source>
              <year>2007</year>
              <volume>14</volume>
              <fpage>1439</fpage>
              <lpage>41</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(6 year old girl with epilepsy developed rash, fever and eosinophilia 3 weeks after starting phenobarbital [ALT 5 times ULN, Alk P 1.5 times ULN], improving clinically with corticosteroid therapy; switched to topiramate and valproate without recurrence).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17997290</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.tohyama.2007.934">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Tohyama</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Hashimoto</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Yasukawa</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Association of human herpes virus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome.</article-title>
              <source>Br J Dermatol</source>
              <year>2007</year>
              <volume>157</volume>
              <fpage>934</fpage>
              <lpage>40</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Anti-HHV-6 testing of 100 patients with drug induced hypersensitivity syndrome [34% with hepatitis] found rise in IgG levels in 62 patients, largely in more severe cases; HHV-6 DNA detected in 18; drugs included carbamazepine, phenobarbital, phenytoin, allopurinol, sulfasalazine and mexiletine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17854362</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.di_mizio.2007.653">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Di Mizio</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Gambardella</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Labate</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Perna</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Ricci</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Quattrone</surname>
                  <given-names>A</given-names>
                </name>
              </person-group>
              <article-title>Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.</article-title>
              <source>Seizure</source>
              <year>2007</year>
              <volume>16</volume>
              <fpage>653</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Two men, ages 44 and 40 years, on long term phenobarbital had sudden death and were found to have granulomas and portal inflammation on autopsy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">17574447</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.bj_rnsson.2008.281">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>E.</given-names>
                </name>
              </person-group>
              <article-title>Hepatotoxicity associated with antiepileptic drugs.</article-title>
              <source>Acta Neurol Scand</source>
              <year>2008</year>
              <volume>118</volume>
              <fpage>281</fpage>
              <lpage>90</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of anticonvulsant hepatotoxicity, mentions that phenytoin associated liver injury usually occurs as a part of a hypersensitivity syndrome, in 1:10,000 to 1:50,000 persons, 100 published cases, mean onset at 4 weeks, 13% mortality; in contrast, phenobarbital has only rarely been reported to cause liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18341684</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Watkins</surname>
                  <given-names>PB</given-names>
                </name>
                <name name-style="western">
                  <surname>Davern</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Serrano</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Rochon</surname>
                  <given-names>J</given-names>
                </name>
                <collab>Drug Induced Liver Injury Network (DILIN)</collab>
              </person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, 18 cases were attributed to anticonvulsants, no case was attributed to phenobarbital).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.ferrajolo.2010.721">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ferrajolo</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Capuano</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Verhamme</surname>
                  <given-names>KM</given-names>
                </name>
                <name name-style="western">
                  <surname>Schuemie</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Rossi</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Stricker</surname>
                  <given-names>BH</given-names>
                </name>
                <name name-style="western">
                  <surname>Sturkenboom</surname>
                  <given-names>MC</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.</article-title>
              <source>Br J Clin Pharmacol</source>
              <year>2010</year>
              <volume>70</volume>
              <fpage>721</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, phenobarbital accounting for 41 cases [0.4%] for an adjusted odds ratio of 6.6).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21039766</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.molleston.2011.182">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Molleston</surname>
                  <given-names>JP</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Lopez</surname>
                  <given-names>MJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Kleiner</surname>
                  <given-names>DE</given-names>
                </name>
                <name name-style="western">
                  <surname>Gu</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <collab>Drug-Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN Prospective Study.</article-title>
              <source>J Pediatr Gastroenterol Nutr</source>
              <year>2011</year>
              <volume>53</volume>
              <fpage>182</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 30 children with drug induced liver injury enrolled in a prospective US database between 2004 and 2008, 8 were due to anticonvulsants [lamotrigine in 3, valproate in 3, phenytoin in 1 and carbamazepine in 1], none were attributed to phenobarbital).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21788760</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.zhang.2011.349">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Zhang</surname>
                  <given-names>LL</given-names>
                </name>
                <name name-style="western">
                  <surname>Zeng</surname>
                  <given-names>LN</given-names>
                </name>
                <name name-style="western">
                  <surname>Li</surname>
                  <given-names>YP</given-names>
                </name>
              </person-group>
              <article-title>Side effects of phenobarbital in epilepsy: a systematic review.</article-title>
              <source>Epileptic Disord</source>
              <year>2011</year>
              <volume>13</volume>
              <fpage>349</fpage>
              <lpage>65</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the side effects of phenobarbital focusing upon cognitive adverse effects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21926048</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF42">
            <element-citation publication-type="journal">
              <article-title>Drugs for epilepsy.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2013</year>
              <volume>11</volume>
              <fpage>9</fpage>
              <lpage>18</lpage>
              <comment>Erratum in Treat Guidel Med Lett 2013; 11: 112</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise review and guidelines to use of anticonvulsants; phenobarbital is listed under "other drugs" and said to be effective for partial and secondarily generalized tonic-clonic seizures; no mention of hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23348233</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Bergmann</surname>
                  <given-names>OM</given-names>
                </name>
                <name name-style="western">
                  <surname>Bj&#x000f6;rnsson</surname>
                  <given-names>HK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kvaran</surname>
                  <given-names>RB</given-names>
                </name>
                <name name-style="western">
                  <surname>Olafsson</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, including 1 attributed to phenytoin among only 410 persons receiving the drug in Iceland; none were attributed to phenobarbital).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, 7 [4%] of which were attributed to anticonvulsants including 3 to phenytoin, 3 to valproate and 1 to carbamazepine, but none were attributed to phenobarbital).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.devarbhavi.2014.145">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Devarbhavi</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Andrade</surname>
                  <given-names>RJ</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs.</article-title>
              <source>Semin Liver Dis</source>
              <year>2014</year>
              <volume>34</volume>
              <fpage>145</fpage>
              <lpage>61</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of drug induced liver injury caused by several drug classes including antiepileptics, which account for 2-11% of all cases in various registries; a common presentation is with DRESS, particularly with the older agents such as carbamazepine, phenytoin and phenobarbital and often associated with reactivation of human herpes virus 6 or 7).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24879980</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 40 [4.5%] were due to anticonvulsants including 12 due to phenytoin, 9 lamotrigine, 7 valproate, 4 carbamazepine, 3 gabapentin, 2 topiramate and 1 each for ethosuximide, fosphenytoin, and pregabalin; but none were attributed to phenobarbital).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.chalasani.2017.1382">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KRK</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>RJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Barnhart</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Gu</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Hayashi</surname>
                  <given-names>PH</given-names>
                </name>
                <name name-style="western">
                  <surname>Ahmad</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Navarro</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Hoofnagle</surname>
                  <given-names>JH</given-names>
                </name>
              </person-group>
              <article-title>Idiosyncratic drug induced liver injury in African-Americans is associated with greater morbidity and mortality compared to Caucasians.</article-title>
              <source>Am J Gastroenterol</source>
              <year>2017</year>
              <volume>112</volume>
              <fpage>1382</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among subjects enrolled in a US prospective database of drug induced liver injury, causes more frequent in African Americans than Caucasian were trimethoprim/sulfamethoxazole, methyldopa, phenytoin and allopurinol, and African Americans were more likely to have severe skin adverse events [2.1% vs 0.4%], fatal or transplantation outcomes [10% vs 6%] as well as chronic injury [24% vs 16%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28762375</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.vidaurre.2017.23">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Vidaurre</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Gedela</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Yarosz</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Antiepileptic drugs and liver disease.</article-title>
              <source>Pediatr Neurol</source>
              <year>2017</year>
              <volume>77</volume>
              <fpage>23</fpage>
              <lpage>36</lpage>
              <annotation>
                <p><italic toggle="yes">(Review of the use of anticonvulsants in patients with liver disease recommends use of agents that have little hepatic metabolism such as</italic>&#x000a0;<italic toggle="yes">levetiracetam</italic><italic toggle="yes">, lacosamide, topiramate, gabapentin and pregabalin,</italic>&#x000a0;<italic toggle="yes">levetiracetam</italic>&#x000a0;<italic toggle="yes">being an "ideal" first line therapy for patients with liver disease because of its safety and lack of pharmacokinetic interactions).</italic></p>
              </annotation>
              <pub-id pub-id-type="pmid">29097018</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF49">
            <element-citation publication-type="journal">
              <article-title>Drugs for epilepsy.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2017</year>
              <volume>59</volume>
              <issue>1526</issue>
              <fpage>121</fpage>
              <lpage>30</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Concise review of the drugs available for therapy of epilepsy mentions that phenobarbital and primidone are effects for therapy of partial and secondarily generalized tonic-clonic seizures, but have a higher incidence of sedation that other drugs).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28746301</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.borrelli.2018.2318">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Borrelli</surname>
                  <given-names>EP</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>EY</given-names>
                </name>
                <name name-style="western">
                  <surname>Descoteaux</surname>
                  <given-names>AM</given-names>
                </name>
                <name name-style="western">
                  <surname>Kogut</surname>
                  <given-names>SJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Caffrey</surname>
                  <given-names>AR</given-names>
                </name>
              </person-group>
              <article-title>Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.</article-title>
              <source>Epilepsia</source>
              <year>2018</year>
              <volume>59</volume>
              <fpage>2318</fpage>
              <lpage>24</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of adverse event reports to the FDA between 2014 and 2018 identified ~2.9 million reports, 1034 for SJS/TEN, the most common class of drugs being anticonvulsants with 17 of 34 having at least one report, those most frequently linked being lamotrigine [n=106], carbamazepine [22], levetiracetam [14], phenytoin [14], valproate [9], clonazepam [8] and zonisamide [7], whereas phenobarbital is not listed; no mention of accompanying liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30395352</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.han.2019.324">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Han</surname>
                  <given-names>XD</given-names>
                </name>
                <name name-style="western">
                  <surname>Koh</surname>
                  <given-names>MJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Wong</surname>
                  <given-names>SMY</given-names>
                </name>
              </person-group>
              <article-title>Drug reaction with eosinophilia and systemic symptoms in a cohort of Asian children.</article-title>
              <source>Pediatr Dermatol</source>
              <year>2019</year>
              <volume>36</volume>
              <fpage>324</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 10 children with DRESS syndrome seen at a single, Singapore referral center between 2006 and 2016, 3 cases were attributed to sulfamethoxazole/trimethoprim, 2 to carbamazepine, 1 sulfasalazine, 2 phenobarbital and 1 to levetiracetam [latency 28 days]; all had ALT elevations [88 to 1172 U/L], bilirubin was elevated in 7, but none had acute liver failure and none were fatal).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30920020</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.canopaniagua.2019.501">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Cano-Paniagua</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Amariles</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Angulo</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Restrepo-Garay</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Epidemiology of drug-induced liver injury in a University Hospital from Colombia: Updated RUCAM being used for prospective causality assessment.</article-title>
              <source>Ann Hepatol</source>
              <year>2019</year>
              <volume>18</volume>
              <fpage>501</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 286 patients with liver test abnormalities seen in a single hospital in Colombia over a 1 year period, 17 were diagnosed with drug induced liver injury, the most common cause being antituberculosis therapy [n=6] followed by anticonvulsants [n=3, 1 each due to phenytoin, gabapentin and valproate]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31053545</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.sridharan.2020.100580">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sridharan</surname>
                  <given-names>K</given-names>
                </name>
                <name name-style="western">
                  <surname>Daylami</surname>
                  <given-names>AA</given-names>
                </name>
                <name name-style="western">
                  <surname>Ajjawi</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Ajooz</surname>
                  <given-names>HAMA</given-names>
                </name>
              </person-group>
              <article-title>Drug-induced liver injury in critically ill children taking antiepileptic drugs: a retrospective study.</article-title>
              <source>Curr Ther Res Clin Exp</source>
              <year>2020</year>
              <volume>92</volume>
              <elocation-id>100580</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 41 children admitted to a pediatric intensive care unit who received anticonvulsants for seizure control, 5 of 9 receiving phenobarbital alone, 9 of 12 receiving phenytoin alone but none of six receiving valproate developed liver test abnormalities [all hepatocellular], the timing, height and outcome of which were not given).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">32280391</pub-id>
            </element-citation>
          </ref>
          <ref id="Phenobarbital.REF.sharpe.2020.e20193182">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sharpe</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Reiner</surname>
                  <given-names>GE</given-names>
                </name>
                <name name-style="western">
                  <surname>Davis</surname>
                  <given-names>SL</given-names>
                </name>
                <name name-style="western">
                  <surname>Nespeca</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Gold</surname>
                  <given-names>JJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Rasmussen</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Kuperman</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>NEOLEV2 INVESTIGATORS. Levetiracetam versus phenobarbital for neonatal seizures: a randomized controlled trial.</article-title>
              <source>Pediatrics</source>
              <year>2020</year>
              <volume>145</volume>
              <elocation-id>e20193182</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 83 newborns with seizures of any caused treated with intravenous phenobarbital or levetiracetam for 5 days, seizure-free status at 24 hours was achieved more frequently with phenobarbital [80% vs 38%] which also had more frequent side effects; monitoring of laboratory data demonstrated &#x0201c;no significant treatment-emergent trends&#x0201d;).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">32385134</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Phenobarbital.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(phenobarbital/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%222009/11/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Phenobarbital: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=phenobarbital">Trials on Phenobarbital: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
